Metformin targets multiple signaling pathways in cancer

被引：11

作者：

Yong Lei ^{[1
,2
]}

Yanhua Yi ^{[3
]}

Yang Liu ^{[1
,2
]}

Xia Liu ^{[1
,2
]}

Evan TKeller ^{[4
]}

ChaoNan Qian ^{[5
]}

Jian Zhang ^{[1
,2
,4
]}

Yi Lu ^{[1
,2
]}

机构：

[1] Key Laboratory of Longevity and Ageing-related Diseases,Ministry of Education

[2] Center for Translational Medicine,Guangxi Medical University

[3] School for International Education,Guangxi Medical University

[4] Department of Urology and Pathology,School of Medicine,University of Michigan

[5] Department of Nasopharyngeal Carcinoma,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center

来源：

Chinese Journal of Cancer | 2017年 / 36卷 / 07期

关键词：

Metformin; Signaling pathway; Cancer stem cell; Cancer;

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

100214 ;

摘要：

Metformin,an inexpensive and well-tolerated oral agent commonly used in the first-line treatment of type 2 diabetes,has become the focus of intense research as a candidate anticancer agent.Here,we discuss the potential of metformin in cancer therapeutics,particularly its functions in multiple signaling pathways,including AMP-activated protein kinase,mammalian target of rapamycin,insulin-like growth factor,c-Jun N-terminal kinase/mitogen-activated protein kinase(p38 MARK),human epidermal growth factor receptor-2,and nuclear factor kappaB pathways.In addition,cutting-edge targeting of cancer stem cells by metformin is summarized.

引用

页码：289 / 297

页数：9